HBM Holdings Receives Upfront Payment, Stake for Immunological Diseases Antibody

Like
Comment
Favorite

HBM Holdings Receives Upfront Payment, Stake for Immunological Diseases Antibody

MT Newswires Live03-06

HBM Holdings (HKG:2142) received an upfront payment for its licensing agreement with Windward Bio AG, along with an equity interest in the latter's parent company, a Thursday Hong Kong bourse filing said.

The company and Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) had agreed to grant an exclusive license for their jointly developed HBM9378/SKB378, an anti-TSLP fully human antibody for immunological diseases, to Windward Bio, which could commercialize the drug worldwide aside from greater China and some other Southeast and West Asian countries.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

01:49
Advance ZincTek - Plan to Increase Stock Levels and Ship to USA Over Next 6 Months to Avoid Additional Costs to USA Customers
01:47
Japan's Nikkei Share Average Pares Gains, Last up 0.34%
01:45
S&P Global Ratings- Tightening Regulations in Indian Microfinance to Rein in Growth Plans for Sector Lenders
01:31
China's Yuan Opens Trade at 7.2600 per Dollar VS Last Close at 7.2593
01:27
Pakistan Ambassador to China, on China's Proposed Joint Security System: There Is a High Degree of Trust Between US, We Will Continue to Take Measures Which Are Effective

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2517185660?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-06 14:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517185660","market":"us","top_or_hot":-1,"title":"HBM Holdings Receives Upfront Payment, Stake for Immunological Diseases Antibody","media":"MT Newswires Live","content":"<html><body><p> HBM Holdings (HKG:2142) received an upfront payment for its licensing agreement with Windward Bio AG, along with an equity interest in the latter's parent company, a Thursday Hong Kong bourse filing said.</p><p>The company and Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) had agreed to grant an exclusive license for their jointly developed HBM9378/SKB378, an anti-TSLP fully human antibody for immunological diseases, to Windward Bio, which could commercialize the drug worldwide aside from greater China and some other Southeast and West Asian countries.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM Holdings Receives Upfront Payment, Stake for Immunological Diseases Antibody</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM Holdings Receives Upfront Payment, Stake for Immunological Diseases Antibody\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-06 14:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> HBM Holdings (HKG:2142) received an upfront payment for its licensing agreement with Windward Bio AG, along with an equity interest in the latter's parent company, a Thursday Hong Kong bourse filing said.</p><p>The company and Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) had agreed to grant an exclusive license for their jointly developed HBM9378/SKB378, an anti-TSLP fully human antibody for immunological diseases, to Windward Bio, which could commercialize the drug worldwide aside from greater China and some other Southeast and West Asian countries.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物-B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2517185660","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517185660","pubTimestamp":1741243252,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"HBM Holdings  received an upfront payment for its licensing agreement with Windward Bio AG, along with an equity interest in the latter's parent company, a Thursday Hong Kong bourse filing said.The company and Sichuan Kelun-Biotech Biopharmaceutical  had agreed to grant an exclusive license for their jointly developed HBM9378/SKB378, an anti-TSLP fully human antibody for immunological diseases, to Windward Bio, which could commercialize the drug worldwide aside from greater China and some other Southeast and West Asian countries.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物-B","BK1161":"生物科技","BK1574":"生物医药B类股","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","BK1583":"高瓴概念","02142":"和铂医药-B"},"translate_title":"HBM Holdings收到免疫疾病抗体的预付款和股份","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":0.9,"06990":0.9},"content_text":"HBM Holdings (HKG:2142) received an upfront payment for its licensing agreement with Windward Bio AG, along with an equity interest in the latter's parent company, a Thursday Hong Kong bourse filing said.The company and Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) had agreed to grant an exclusive license for their jointly developed HBM9378/SKB378, an anti-TSLP fully human antibody for immunological diseases, to Windward Bio, which could commercialize the drug worldwide aside from greater China and some other Southeast and West Asian countries.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}